ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN THE TREATMENT OF LEUKEMIA

We reported 14 leukemia patients transplantedwith allogeneic peripheral blood stem cells (Allo-PBSCT)of HLA identical sibling, AML 5, ALL 4, CML 5. Therewere 12 patients in their early stage of leukemia, 2 in latestage. They were 32 (25-42) years old, 10 male and 4female. After conditioned with CTX and fTBI, G/GM-CSF mobilized donor’s peripheral blood mononuclearcells (MNC) 4.80 (2-46-8.43) × 108/kg and CD34+ cells3.96 (1.01-10.08) × 106 /kg were infused respectively. CSAand MTX used as GVHD prophylaxis. After Allo-PBSCT,WBC rose to 1.0 × 109 /L on day + 17 (+12 - +26) andplatelet rose to 50 x 109/L on day +27 (+19 - +35)respectively- The blood products support, the antibioticsused, and total environment protection durationdecreased. Acute GVHD presented in 7 patients (50.0o/o).Four patients died in acute GVHD and infection on daysof +73, +41 +57 and +49. The disease free survival daysafter Allo-PBSCT in the 10 patients was +137 (+91 -+240) days. It is suggested that Allo-PBSCT probably hassome advantage than that of Allo-BMT.